These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19602998)

  • 1. Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model.
    Dhar D; Spencer JF; Toth K; Wold WS
    Mol Ther; 2009 Oct; 17(10):1724-32. PubMed ID: 19602998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters.
    Dhar D; Spencer JF; Toth K; Wold WS
    J Virol; 2009 Mar; 83(5):2130-9. PubMed ID: 19073718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters.
    Dhar D; Toth K; Wold WS
    Cancer Gene Ther; 2014 Apr; 21(4):171-8. PubMed ID: 24722357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies.
    Ying B; Toth K; Spencer JF; Meyer J; Tollefson AE; Patra D; Dhar D; Shashkova EV; Kuppuswamy M; Doronin K; Thomas MA; Zumstein LA; Wold WS; Lichtenstein DL
    Cancer Gene Ther; 2009 Aug; 16(8):625-37. PubMed ID: 19197322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector.
    Lichtenstein DL; Spencer JF; Doronin K; Patra D; Meyer JM; Shashkova EV; Kuppuswamy M; Dhar D; Thomas MA; Tollefson AE; Zumstein LA; Wold WS; Toth K
    Cancer Gene Ther; 2009 Aug; 16(8):644-54. PubMed ID: 19197324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Syrian hamster tumor model to study oncolytic Ad5-based vectors.
    Dhar D; Toth K; Wold WS
    Methods Mol Biol; 2012; 797():53-63. PubMed ID: 21948468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster.
    Spencer JF; Sagartz JE; Wold WS; Toth K
    Cancer Gene Ther; 2009 Dec; 16(12):912-22. PubMed ID: 19478829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors.
    Young BA; Spencer JF; Ying B; Tollefson AE; Toth K; Wold WS
    Cancer Gene Ther; 2013 Sep; 20(9):521-30. PubMed ID: 23928731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclophosphamide enhances antitumor efficacy of oncolytic adenovirus expressing uracil phosphoribosyltransferase (UPRT) in immunocompetent Syrian hamsters.
    Hasegawa N; Abei M; Yokoyama KK; Fukuda K; Seo E; Kawashima R; Nakano Y; Yamada T; Nakade K; Hamada H; Obata Y; Hyodo I
    Int J Cancer; 2013 Sep; 133(6):1479-88. PubMed ID: 23444104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors.
    Thomas MA; Spencer JF; Wold WS
    Methods Mol Med; 2007; 130():169-83. PubMed ID: 17401172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting.
    Clubb JHA; Kudling TV; Girych M; Haybout L; Pakola S; Hamdan F; Cervera-Carrascon V; Hemmes A; Grönberg-Vähä-Koskela S; Santos JM; Quixabeira DCA; Basnet S; Heiniö C; Arias V; Jirovec E; Kaptan S; Havunen R; Sorsa S; Erikat A; Schwartz J; Anttila M; Aro K; Viitala T; Vattulainen I; Cerullo V; Kanerva A; Hemminki A
    Front Immunol; 2023; 14():1060540. PubMed ID: 36817448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model.
    Thomas MA; Spencer JF; Toth K; Sagartz JE; Phillips NJ; Wold WS
    Mol Ther; 2008 Oct; 16(10):1665-73. PubMed ID: 18665155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of radiation on antitumor efficacy of an oncolytic adenovirus vector in the Syrian hamster model.
    Young BA; Spencer JF; Ying B; Toth K; Wold WS
    Cancer Gene Ther; 2013 Sep; 20(9):531-7. PubMed ID: 23928730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression.
    Rodríguez-García A; Giménez-Alejandre M; Rojas JJ; Moreno R; Bazan-Peregrino M; Cascalló M; Alemany R
    Clin Cancer Res; 2015 Mar; 21(6):1406-18. PubMed ID: 25391696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors.
    Thomas MA; Spencer JF; La Regina MC; Dhar D; Tollefson AE; Toth K; Wold WS
    Cancer Res; 2006 Feb; 66(3):1270-6. PubMed ID: 16452178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
    Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
    Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A fully replication-competent adenovirus vector with enhanced oncolytic properties.
    Toth K; Kuppuswamy M; Shashkova EV; Spencer JF; Wold WS
    Cancer Gene Ther; 2010 Nov; 17(11):761-70. PubMed ID: 20596091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice.
    Varnavski AN; Calcedo R; Bove M; Gao G; Wilson JM
    Gene Ther; 2005 Mar; 12(5):427-36. PubMed ID: 15647774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters.
    Kim JW; Auffinger B; Spencer DA; Miska J; Chang AL; Kane JR; Young JS; Kanojia D; Qiao J; Mann JF; Zhang L; Wu M; Ahmed AU; Aboody KS; Strong TV; Hébert CD; Lesniak MS
    J Transl Med; 2016 May; 14(1):134. PubMed ID: 27184224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.
    Cerullo V; Diaconu I; Kangasniemi L; Rajecki M; Escutenaire S; Koski A; Romano V; Rouvinen N; Tuuminen T; Laasonen L; Partanen K; Kauppinen S; Joensuu T; Oksanen M; Holm SL; Haavisto E; Karioja-Kallio A; Kanerva A; Pesonen S; Arstila PT; Hemminki A
    Mol Ther; 2011 Sep; 19(9):1737-46. PubMed ID: 21673660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.